Welcome to our dedicated page for BCYP news (Ticker: BCYP), a resource for investors and traders seeking the latest updates and insights on BCYP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BCYP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BCYP's position in the market.
Big Cypress Acquisition Corp. (NASDAQ: BCYP) announced that Eddie J. Sullivan, CEO of SAB Biotherapeutics, presented at the Ladenburg Thalmann Annual Healthcare Conference. The presentation highlighted SAB's innovative immunotherapy platform, which focuses on high potency, fully-human polyclonal antibody therapeutics. Big Cypress is preparing to merge with SAB, a clinical-stage biopharmaceutical company, with the transaction expected to close in Q4 2021. This merger aims to enhance Big Cypress's portfolio in the life sciences sector.
SAB Biotherapeutics announced that its CEO, Eddie J. Sullivan, will present at the Ladenburg Thalmann Annual Healthcare Conference on July 13, 2021. The company is a clinical-stage biopharmaceutical firm focusing on immunotherapy solutions using human polyclonal antibodies. Additionally, SAB revealed a planned merger with Big Cypress Acquisition Corp. (NASDAQ: BCYP), set to close in Q4 2021. SAB's innovative DiversitAb platform enables rapid production of targeted high-potency antibodies for various diseases, including COVID-19 and cancer.
Big Cypress Acquisition Corp. (NASDAQ: BCYP) has submitted a draft registration statement on Form S-4 to the SEC for its proposed merger with SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company. This marks a significant step toward finalizing the merger, which aims to enhance SAB's innovative immunotherapy platform. CEO Samuel J. Reich highlighted the progress of SAB’s clinical programs, including a Phase 2a study for influenza and a U.S. government-sponsored trial for COVID-19. The merger is anticipated to close in Q4 2021.
SAB Biotherapeutics has announced a merger with Big Cypress Acquisition Corp. (NASDAQ: BCYP), positioning the combined entity to operate as SAB Biotherapeutics. The merger values SAB at approximately $325 million, providing around $118 million in post-merger cash for development. SAB's proprietary DiversitAb™ platform aims to produce fully-human antibodies for diseases like COVID-19 and cancer. The merger is backed by both companies' boards and is set to close in Q4 2021, subject to stockholder approval and regulatory conditions.
Big Cypress Acquisition Corp. announced that, starting February 9, 2021, holders of its initial public offering's 11,500,000 units can separately trade common stock and redeemable warrants. The units will continue to trade under the symbol BCYPU, while the common stock and warrants will trade under BCYP and BCYPW, respectively. Holders must contact their brokers for the separation process. Ladenburg Thalmann acted as the sole book running manager, with Brookline Capital Markets as co-manager. The SEC declared the relevant registration statement effective on January 11, 2021.
Big Cypress Acquisition Corp. completed its initial public offering, closing on January 14, 2021, with 11,500,000 units sold at $10.00 per unit. The offering garnered total gross proceeds of $115,000,000. Each unit comprises one share of common stock and one-half of a redeemable warrant. The units began trading on Nasdaq under the symbol BCYPU on January 12, 2021. Ladenburg Thalmann served as sole book running manager of the offering, with legal counsel provided by Dentons US LLP and Graubard Miller.